DNA methylation at enhancers identifies distinct breast cancer lineages

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Fleischer, Thomas ^a   Tekpli, Xavier ^a,b   Mathelier, Anthony ^a,c   Wang, Shixiong ^c   Nebdal, Daniel ^a   Dhakal, Hari P ^d   Sahlberg, Kristine Kleivi ^a,e   Schlichting, Ellen ^d   Sauer, Torill ^b   Geisler, Jürgen ^b   Hofvind, Solveig ^h,i   Bathen, Tone F ^j   Engebraaten, Olav ^d,g   Garred, Øystein ^d   Geitvik, Gry Aarum ^a   Langerød, Anita ^a   Kåresen, Rolf ^d,g   Mælandsmo, Gunhild Mari ^d,k   Russnes, Hege G ^a,d   Sørlie, Therese ^a   Lingjærde, Ole Christian ^c   Skjerven, Helle Kristine ^e   Park, Daehoon ^e   Fritzman, Britt ^l   Børresen Dale, Anne Lise ^a   Borgen, Elin ^d   Naume, Bjørn ^d   Eskeland, Ragnhild ^c,d   Frigessi, Arnoldo ^c   Tost, Jörg ^f   Hurtado, Antoni ^a,c   Kristensen, Vessela N ^a,b,g   more..

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e VESTRE VIKEN HOSPITAL TRUST   (Norway)

^f CENTRE NATIONAL DE GÉNOTYPAGE   (France)

^g UNIVERSITY OF OSLO   (Norway)

^h CANCER REGISTRY OF NORWAY   (Norway)

ⁱ OSLO METROPOLITAN UNIVERSITY   (Norway)

^j NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^k UNIVERSITY OF TROMSØ   (Norway)

^l Østfold Hospital   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ESTROGEN RECEPTOR ALPHA; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTOME; ESTROGEN RECEPTOR ALPHA, HUMAN; FOXA1 PROTEIN, HUMAN; GATA3 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

BIOTRANSFORMATION; CANCER; CELLS AND CELL COMPONENTS; COHORT ANALYSIS; CYTOGENETICS; DNA; GENE EXPRESSION; GENETIC ANALYSIS; GENOME; IMMUNE SYSTEM; IMMUNOASSAY; METHYLATION; RNA; TUMOR;

ARTICLE; BREAST CANCER; CHROMATIN IMMUNOPRECIPITATION; COHORT ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; ENHANCER REGION; FEMALE; GENE EXPRESSION; GENE SILENCING; GENOME ANALYSIS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; QUANTITATIVE TRAIT LOCUS; TRANSCRIPTOMICS; BINDING SITE; BREAST TUMOR; CPG ISLAND; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MCF-7 CELL LINE; METABOLISM; REPRODUCIBILITY;

BINDING SITES; BREAST NEOPLASMS; CPG ISLANDS; DNA METHYLATION; ENHANCER ELEMENTS, GENETIC; EPIGENESIS, GENETIC; ESTROGEN RECEPTOR ALPHA; FEMALE; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; MCF-7 CELLS; QUANTITATIVE TRAIT LOCI; REPRODUCIBILITY OF RESULTS; TRANSCRIPTION FACTORS;

EID: 85033801233     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-00510-x     Document Type: Article

References (62)

1. van Hoesel, A. Q. et al. Assessment of DNA methylation status in early stages of breast cancer development. Br. J. Cancer 108, 2033-2038 (2013).
2. Jovanovic, J., Ronneberg, J. A., Tost, J. & Kristensen, V. The epigenetics of breast cancer. Mol. Oncol. 4, 242-254 (2010).
3. Bediaga, N. G. et al. DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res. 12, R77 (2010).
4. Fackler, M. J. et al. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res. 71, 6195-6207 (2011).
5. Fleischer, T. et al. Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis. Genome. Biol. 15, 435 (2014).
6. Holm, K. et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. 12, R36 (2010).
7. Kamalakaran, S. et al. DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. Mol. Oncol. 5, 77-92 (2011).
8. Ronneberg, J. A. et al. Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol. Oncol. 5, 61-76 (2011).
9. Bulger, M. & Groudine, M. Functional and mechanistic diversity of distal transcription enhancers. Cell 144, 327-339 (2011).
10. Shlyueva, D., Stampfel, G. & Stark, A. Transcriptional enhancers: from properties to genome-wide predictions. Nat. Rev. Genet. 15, 272-286 (2014).
11. Massie, C. E. & Mills, I. G. ChIPping away at gene regulation. EMBO Rep. 9, 337-343 (2008).
12. Spitz, F. & Furlong, E. E. Transcription factors: from enhancer binding to developmental control. Nat. Rev. Genet. 13, 613-626 (2012).
13. Fullwood, M. J. et al. An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 462, 58-64 (2009).
14. Hah, N., Murakami, S., Nagari, A., Danko, C. G. & Kraus, W. L. Enhancer transcripts mark active estrogen receptor binding sites. Genome Res. 23, 1210-1223 (2013).
15. Hurtado, A., Holmes, K. A., Ross-Innes, C. S., Schmidt, D. & Carroll, J. S. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet. 43, 27-33 (2011).
16. Theodorou, V., Stark, R., Menon, S. & Carroll, J. S. GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Genome Res. 23, 12-22 (2013).
17. Lister, R. et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462, 315-322 (2009).
18. Herman, J. G. & Baylin, S. B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042-2054 (2003).
19. Aure, M. R. et al. Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer. Genome Med. 7, 21 (2015).
20. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
21. Taberlay, P. C., Statham, A. L., Kelly, T. K., Clark, S. J. & Jones, P. A. Reconfiguration of nucleosome-depleted regions at distal regulatory elements accompanies DNA methylation of enhancers and insulators in cancer. Genome Res. 24, 1421-1432 (2014).
22. Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934-947 (2013).
23. Khan, A. & Zhang, X. dbSUPER: a database of super-enhancers in mouse and human genome. Nucleic Acids Res. 44, D164-D171 (2016).
24. Beck, D. et al. Genome-wide analysis of transcriptional regulators in human HSPCs reveals a densely interconnected network of coding and noncoding genes. Blood 122, E12-E22 (2013).
25. Starck, J. et al. Inducible Fli-1 gene deletion in adult mice modifies several myeloid lineage commitment decisions and accelerates proliferation arrest and terminal erythrocytic differentiation. Blood 116, 4795-4805 (2010).
26. Kruse, E. A. et al. Dual requirement for the ETS transcription factors Fli-1 and Erg in hematopoietic stem cells and the megakaryocyte lineage. Proc. Natl Acad. Sci. USA 106, 13814-13819 (2009).
27. Loughran, S. J. et al. The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nat. Immunol. 9, 810-819 (2008).
28. Landt, S. G. et al. ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. Genome Res. 22, 1813-1831 (2012).
29. Nagamura-Inoue, T., Tamura, T. & Ozato, K. Transcription factors that regulate growth and differentiation of myeloid cells. Int. Rev. Immunol. 20, 83-105 (2001).
30. Griffon, A. et al. Integrative analysis of public ChIP-seq experiments reveals a complex multi-cell regulatory landscape. Nucleic Acids Res. 43, e27 (2015).
31. Ross-Innes, C. S. et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389-393 (2012).
32. Teschendorff, A. E. et al. DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer. Nat. Commun. 7, 10478 (2016).
33. Gardini, A. Global run-on sequencing (GRO-Seq). Methods Mol. Biol. 1468, 111-120 (2017).
34. Ju, W. et al. Defining cell-type specificity at the transcriptional level in human disease. Genome Res. 23, 1862-1873 (2013).
35. Zheng, X., Zhang, N., Wu, H. J. & Wu, H. Estimating and accounting for tumor purity in the analysis of DNA methylation data from cancer studies. Genome Biol. 18, 17 (2017).
36. Do, C. et al. Mechanisms and disease associations of haplotype-dependent allele-specific DNA methylation. Am. J. Hum. Genet. 98, 934-955 (2016).
37. de Goede, O. M. et al. Nucleated red blood cells impact DNA methylation and expression analyses of cord blood hematopoietic cells. Clin. Epigenet. 7, 95 (2015).
38. Kananen, L. et al. Aging-associated DNA methylation changes in middle-aged individuals: the Young Finns study. BMC Genomics. 17, 103 (2016).
39. Stone, A. et al. DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer. Nat. Commun. 6, 7758 (2015).
40. Ung, M., Ma, X., Johnson, K. C., Christensen, B. C. & Cheng, C. Effect of estrogen receptor alpha binding on functional DNA methylation in breast cancer. Epigenetics 9, 523-532 (2014).
41. Sproul, D. et al. Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns. Genome Biol. 13, R84 (2012).
42. Kaise, M. et al. CpG island hypermethylation of tumor-suppressor genes in H. pylori-infected non-neoplastic gastric mucosa is linked with gastric cancer risk. Helicobacter 13, 35-41 (2008).
43. Nakajima, T. et al. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol. Biomarkers Prev. 15, 2317-2321 (2006).
44. Ushijima, T. Epigenetic field for cancerization. J. Biochem. Mol. Biol. 40, 142-150 (2007).
45. Quigley, D. A. & Kristensen, V. Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. Mol. Oncol. 9, 2054-2062 (2015).
46. Savas, P. et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat. Rev. Clin. Oncol. 13, 228-241 (2016).
47. Naume, B. et al. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol. Oncol. 1, 160-171 (2007).
48. Enerly, E. et al. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS ONE 6, e16915 (2011).
49. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
50. Touleimat, N. & Tost, J. Complete pipeline for Infinium((R)) Human Methylation 450K BeadChip data processing using subset quantile normalization for accurate DNA methylation estimation. Epigenomics 4, 325-341 (2012).
51. R-Core-Team. R: A language and environment for statistical computing (eds R Foundation for Statistical Computing) (2015).
52. Sun W. eMap: map gene expression qtl. R package version 1.2. (2010).
53. Kolde R. pheatmap: Pretty Heatmaps. R package version 1.0.8. (2015).
54. Krzywinski, M. et al. Circos: an information aesthetic for comparative genomics. Genome Res. 19, 1639-1645 (2009).
55. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576-589 (2010).
56. Khan, A. & Mathelier, A. Intervene: a tool for intersection and visualization of multiple gene or genomic region sets. BMC Bioinform. 18, 287 (2017).
57. Li, G. et al. Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. Cell 148, 84-98 (2012).
58. Feng, J. X., Liu, T., Qin, B., Zhang, Y. & Liu, X. S. Identifying ChIP-seq enrichment using MACS. Nat. Protoc. 7, 1728-1740 (2012).
59. Wang, D. et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474, 390-394 (2011).
60. Schmidt, D. et al. ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. Methods 48, 240-248 (2009).
61. Dhakal, H. P. et al. Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact. Histol. Histopathol. 27, 1315-1325 (2012).
62. Ernst, J. & Kellis, M. ChromHMM: automating chromatin-state discovery and characterization. Nat. Methods 9, 215-216 (2012).